GlassScriptPhysician profile
Mical Shane Campbell
NPI 1083628770
$9,213.95
in general payments reported to CMS, 2019-2025
39 companies · $2,350 in 2025
The $2,350 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,400 · 2020: $291 · 2021: $720 · 2022: $129 · 2023: $2,195 · 2024: $2,129 · 2025: $2,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,644 · Education: $30.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,643.95 |
| Education | $30.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,255.40 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,293.19 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,081.74 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $502.81 | 2019-2025 | |
| Janssen Biotech, INC. | $478.02 | 2019-2025 | Stelara, Tremfya, Simponi |
| Qol Medical, LLC | $356.43 | 2023-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $347.72 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $270.22 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $245.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $232.02 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $173.83 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $171.80 | 2021-2024 | Linzess |
| Exact Sciences Corporation | $167.71 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $159.76 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $144.86 | 2019-2024 | Rebyota |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mical Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.